Use of corticosteroids and the outcome of infants with bronchopulmonary dysplasia

Detalhes bibliográficos
Autor(a) principal: Mataloun,Marta M. G. B.
Data de Publicação: 1999
Outros Autores: Gibelli,Maria Augusta C., Kato,Ana V., Vaz,Flávio Adolfo Costa, Leone,Cléa Rodrigues
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Revista do Hospital das Clínicas
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0041-87811999000600002
Resumo: Ventilator-dependent premature infants are often treated with dexamethasone. Several trials showed that steroids while improve pulmonary compliance and facilitate extubation, some treated infants may have adverse effects, such as alterations of growth curves. We conducted this retrospective study to evaluate the effects of steroids on mechanical ventilation, oxygen therapy, hospital length stay and mortality, in ventilator-dependent infants with bronchopulmonary dysplasia (BPD) (defined as the need of oxygen supplementation at 28 days of life). Twenty-six newborns with BPD were evaluated during 9 -- 42 days postpartum (mean = 31 days) and were divided into two groups: Group I - 14 newborns that did not receive dexamethasone, and Group II - 12 newborns that received dexamethasone at 14 --21 days of life. Dexamethasone was given at a dose of 0.25 mg per kilogram of body weight twice daily intravenously for 3 days, after which the dose was tapered. RESULTS: There were no statistically significant differences in the mean length of mechanical ventilation (Group I - 37 days, Group II - 35 days); oxygen supplementation (Group I - 16 days, Group II - 29 days); hospital stay (Group I - 72 days, Group II - 113 days); mortality (Group I - 35.7%, Group II - 41.6%). At birth, Group II was lighter (BW: Group I - 1154 grams ± 302, Group II - 791 grams ± 165; p < 0.05) and smaller (height: Group I - 37.22 cm ± 3.3, Group II - 33.5 ± 2.4; p< 0.05) than Group I. At 40 weeks, there were no statistically significant differences between groups in relation to anthropometric measurements. CONCLUSIONS: The use of corticosteroids in bronchopulmonary dysplasic infants may influence the somatic growth during its use. However, after its suspension, a recovery seems to occur, suggesting that its influence could be transitory.
id USP-57_e2552eb062e29c0be66df74f740e7cd2
oai_identifier_str oai:scielo:S0041-87811999000600002
network_acronym_str USP-57
network_name_str Revista do Hospital das Clínicas
repository_id_str
spelling Use of corticosteroids and the outcome of infants with bronchopulmonary dysplasiaDexamethasone therapyBronchopulmonary dysplasiaVentilator-dependent premature infants are often treated with dexamethasone. Several trials showed that steroids while improve pulmonary compliance and facilitate extubation, some treated infants may have adverse effects, such as alterations of growth curves. We conducted this retrospective study to evaluate the effects of steroids on mechanical ventilation, oxygen therapy, hospital length stay and mortality, in ventilator-dependent infants with bronchopulmonary dysplasia (BPD) (defined as the need of oxygen supplementation at 28 days of life). Twenty-six newborns with BPD were evaluated during 9 -- 42 days postpartum (mean = 31 days) and were divided into two groups: Group I - 14 newborns that did not receive dexamethasone, and Group II - 12 newborns that received dexamethasone at 14 --21 days of life. Dexamethasone was given at a dose of 0.25 mg per kilogram of body weight twice daily intravenously for 3 days, after which the dose was tapered. RESULTS: There were no statistically significant differences in the mean length of mechanical ventilation (Group I - 37 days, Group II - 35 days); oxygen supplementation (Group I - 16 days, Group II - 29 days); hospital stay (Group I - 72 days, Group II - 113 days); mortality (Group I - 35.7%, Group II - 41.6%). At birth, Group II was lighter (BW: Group I - 1154 grams ± 302, Group II - 791 grams ± 165; p < 0.05) and smaller (height: Group I - 37.22 cm ± 3.3, Group II - 33.5 ± 2.4; p< 0.05) than Group I. At 40 weeks, there were no statistically significant differences between groups in relation to anthropometric measurements. CONCLUSIONS: The use of corticosteroids in bronchopulmonary dysplasic infants may influence the somatic growth during its use. However, after its suspension, a recovery seems to occur, suggesting that its influence could be transitory.Faculdade de Medicina / Universidade de São Paulo - FM/USP1999-12-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0041-87811999000600002Revista do Hospital das Clínicas v.54 n.6 1999reponame:Revista do Hospital das Clínicasinstname:Universidade de São Paulo (USP)instacron:USP10.1590/S0041-87811999000600002info:eu-repo/semantics/openAccessMataloun,Marta M. G. B.Gibelli,Maria Augusta C.Kato,Ana V.Vaz,Flávio Adolfo CostaLeone,Cléa Rodrigueseng2000-07-20T00:00:00Zoai:scielo:S0041-87811999000600002Revistahttp://www.scielo.br/rhcPUBhttps://old.scielo.br/oai/scielo-oai.php||revista.hc@hcnet.usp.br1678-99030041-8781opendoar:2000-07-20T00:00Revista do Hospital das Clínicas - Universidade de São Paulo (USP)false
dc.title.none.fl_str_mv Use of corticosteroids and the outcome of infants with bronchopulmonary dysplasia
title Use of corticosteroids and the outcome of infants with bronchopulmonary dysplasia
spellingShingle Use of corticosteroids and the outcome of infants with bronchopulmonary dysplasia
Mataloun,Marta M. G. B.
Dexamethasone therapy
Bronchopulmonary dysplasia
title_short Use of corticosteroids and the outcome of infants with bronchopulmonary dysplasia
title_full Use of corticosteroids and the outcome of infants with bronchopulmonary dysplasia
title_fullStr Use of corticosteroids and the outcome of infants with bronchopulmonary dysplasia
title_full_unstemmed Use of corticosteroids and the outcome of infants with bronchopulmonary dysplasia
title_sort Use of corticosteroids and the outcome of infants with bronchopulmonary dysplasia
author Mataloun,Marta M. G. B.
author_facet Mataloun,Marta M. G. B.
Gibelli,Maria Augusta C.
Kato,Ana V.
Vaz,Flávio Adolfo Costa
Leone,Cléa Rodrigues
author_role author
author2 Gibelli,Maria Augusta C.
Kato,Ana V.
Vaz,Flávio Adolfo Costa
Leone,Cléa Rodrigues
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Mataloun,Marta M. G. B.
Gibelli,Maria Augusta C.
Kato,Ana V.
Vaz,Flávio Adolfo Costa
Leone,Cléa Rodrigues
dc.subject.por.fl_str_mv Dexamethasone therapy
Bronchopulmonary dysplasia
topic Dexamethasone therapy
Bronchopulmonary dysplasia
description Ventilator-dependent premature infants are often treated with dexamethasone. Several trials showed that steroids while improve pulmonary compliance and facilitate extubation, some treated infants may have adverse effects, such as alterations of growth curves. We conducted this retrospective study to evaluate the effects of steroids on mechanical ventilation, oxygen therapy, hospital length stay and mortality, in ventilator-dependent infants with bronchopulmonary dysplasia (BPD) (defined as the need of oxygen supplementation at 28 days of life). Twenty-six newborns with BPD were evaluated during 9 -- 42 days postpartum (mean = 31 days) and were divided into two groups: Group I - 14 newborns that did not receive dexamethasone, and Group II - 12 newborns that received dexamethasone at 14 --21 days of life. Dexamethasone was given at a dose of 0.25 mg per kilogram of body weight twice daily intravenously for 3 days, after which the dose was tapered. RESULTS: There were no statistically significant differences in the mean length of mechanical ventilation (Group I - 37 days, Group II - 35 days); oxygen supplementation (Group I - 16 days, Group II - 29 days); hospital stay (Group I - 72 days, Group II - 113 days); mortality (Group I - 35.7%, Group II - 41.6%). At birth, Group II was lighter (BW: Group I - 1154 grams ± 302, Group II - 791 grams ± 165; p < 0.05) and smaller (height: Group I - 37.22 cm ± 3.3, Group II - 33.5 ± 2.4; p< 0.05) than Group I. At 40 weeks, there were no statistically significant differences between groups in relation to anthropometric measurements. CONCLUSIONS: The use of corticosteroids in bronchopulmonary dysplasic infants may influence the somatic growth during its use. However, after its suspension, a recovery seems to occur, suggesting that its influence could be transitory.
publishDate 1999
dc.date.none.fl_str_mv 1999-12-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0041-87811999000600002
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0041-87811999000600002
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/S0041-87811999000600002
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Faculdade de Medicina / Universidade de São Paulo - FM/USP
publisher.none.fl_str_mv Faculdade de Medicina / Universidade de São Paulo - FM/USP
dc.source.none.fl_str_mv Revista do Hospital das Clínicas v.54 n.6 1999
reponame:Revista do Hospital das Clínicas
instname:Universidade de São Paulo (USP)
instacron:USP
instname_str Universidade de São Paulo (USP)
instacron_str USP
institution USP
reponame_str Revista do Hospital das Clínicas
collection Revista do Hospital das Clínicas
repository.name.fl_str_mv Revista do Hospital das Clínicas - Universidade de São Paulo (USP)
repository.mail.fl_str_mv ||revista.hc@hcnet.usp.br
_version_ 1754820894003298304